Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Hold” by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given a consensus rating of “Hold” by the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $9.2857.

Several equities research analysts have recently weighed in on the company. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Weiss Ratings upgraded Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC boosted its holdings in shares of Replimune Group by 10.3% in the 4th quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after buying an additional 1,505 shares during the period. JPMorgan Chase & Co. grew its position in shares of Replimune Group by 4.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after buying an additional 1,712 shares during the last quarter. Ballentine Partners LLC raised its stake in Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after acquiring an additional 1,721 shares during the period. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC lifted its holdings in Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after acquiring an additional 2,192 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of REPL stock opened at $11.91 on Thursday. The company’s fifty day simple moving average is $9.63 and its 200-day simple moving average is $7.41. Replimune Group has a 52 week low of $1.50 and a 52 week high of $12.60. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The company has a market cap of $1.00 billion, a PE ratio of -3.52 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts anticipate that Replimune Group will post -2.44 EPS for the current year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.